Diplomat to distribute SYNRIBO® (OMACETAXINE MEPESUCCINATE) for Injection
FLINT, Mich. — Sept. 3, 2014 — Diplomat, the nation’s largest independent specialty pharmacy, announced that it will be the exclusive distributor for SYNRIBO® (omacetaxine mepesuccinate) for subcutaneous injection intended for home use.
On May 5, 2014, the U.S. Food and Drug Administration (FDA) expanded the indication of SYNRIBO® to allow for home administration. SYNRIBO® is a prescription medicine used to treat adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) who are no longer responding to and/or who could not tolerate, two or more tyrosine kinase inhibitors (TKI).
The updated labeling for the product gives prescribers the option to allow patients to administer SYNRIBO® therapy at home. Previously, it was necessary for adults living with chronic or accelerated phase CML who were prescribed SYNRIBO® to travel to their doctor’s office twice a day during active treatment to receive their therapy. The administration schedule was burdensome for some patients and their caregivers and created a potential barrier to treatment. According to the American Cancer Society, a little more than 10 percent of leukemia diagnoses each year are CML, which affects the blood and bone marrow.
SYNRIBO® is manufactured by Teva Pharmaceutical Industries Ltd. For full prescribing information, visit the manufacturer’s website.
Diplomat serves patients and physicians in all 50 states as the nation’s largest independent specialty pharmacy. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues – always focused on improving adherence and outcomes. For more information visit diplomat.is.
Gary Rice, Diplomat
810.768.9863 | firstname.lastname@example.org
@DiplomatRxJoin Cheryl Allen at CBI’s “Patient Journey Mapping—From Diagnosis to Treatment.” Get the latest information on pat… https://t.co/TdFgJ7IaVt2 days ago
@SpecialtyPTimes2 days ago
@SpecialtyPTimesRT @SpecialtyPTimes: Adjuvant Renal Cell Carcinoma Drug Receives FDA Greenlight https://t.co/41wVcPE8fE #Cancer #RCC2 days ago
@DiplomatRxDiplomat to Acquire LDI Integrated Pharmacy Services https://t.co/l9hgIF91i52 weeks ago
@BusLeadersforMIRT @BusLeadersforMI: VIDEO: Phil Hagerman of @DiplomatRx @SkypointFlint gets the crowd at the 2017 #MICEOSummit fired up about Flint! https…2 weeks ago